A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SUNFISH
- Sponsors Chugai Pharmaceutical; Roche
- 09 Nov 2017 Planned End Date changed from 31 May 2020 to 5 May 2020.
- 20 Oct 2017 Protocol was amended to change the design keywords from parallel to sequential and change in treatment groups.
- 20 Oct 2017 Planned number of patients changed from 218 to 219.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History